Issue navigation
Volume 112, Issue 10, October 2020
Editorials
What’s Missing in the Assessment of Adolescent and Young Adult (AYA) Cancer Outcomes?
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 10, October 2020, Pages 975–976, https://doi.org/10.1093/jnci/djaa015
Identifying Novel Genetic Markers Through a Transcription-Wide Association Study: Can This Be a Path to Reducing the Burden of Pancreatic Cancer?
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 10, October 2020, Pages 977–978, https://doi.org/10.1093/jnci/djz247
Review
A Systematic Review of Estimating Breast Cancer Recurrence at the Population Level With Administrative Data
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 10, October 2020, Pages 979–988, https://doi.org/10.1093/jnci/djaa050
Commentary
The Value of All-Cause Mortality as a Metric for Assessing Breast Cancer Screening
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 10, October 2020, Pages 989–993, https://doi.org/10.1093/jnci/djaa025
Articles
Trends in Late Mortality Among Adolescent and Young Adult Cancer Survivors
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 10, October 2020, Pages 994–1002, https://doi.org/10.1093/jnci/djaa014
A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 10, October 2020, Pages 1003–1012, https://doi.org/10.1093/jnci/djz246
Lifetime Benefits and Harms of Prostate-Specific Antigen–Based Risk-Stratified Screening for Prostate Cancer
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 10, October 2020, Pages 1013–1020, https://doi.org/10.1093/jnci/djaa001
The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 10, October 2020, Pages 1021–1029, https://doi.org/10.1093/jnci/djz245
Durability of Cross-Protection by Different Schedules of the Bivalent HPV Vaccine: The CVT Trial
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 10, October 2020, Pages 1030–1037, https://doi.org/10.1093/jnci/djaa010
Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 10, October 2020, Pages 1038–1046, https://doi.org/10.1093/jnci/djaa011
Oral Leukoplakia and Risk of Progression to Oral Cancer: A Population-Based Cohort Study
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 10, October 2020, Pages 1047–1054, https://doi.org/10.1093/jnci/djz238
Oral Oncology Parity Laws, Medication Use, and Out-of-Pocket Spending for Patients With Blood Cancers
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 10, October 2020, Pages 1055–1062, https://doi.org/10.1093/jnci/djz243
Brief Communication
Colorectal Cancer Care Among Young Adult Patients After the Dependent Coverage Expansion Under the Affordable Care Act
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 10, October 2020, Pages 1063–1066, https://doi.org/10.1093/jnci/djz235
Correspondence
Re: Prostate Cancer Incidence 5 Years After US Preventive Services Task Force Recommendations Against Screening
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 10, October 2020, Pages 1067–1068, https://doi.org/10.1093/jnci/djaa092
Response
Response to Lehrer and Rheinstein
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 10, October 2020, Pages 1069–1070, https://doi.org/10.1093/jnci/djaa093
Erratum
Erratum: Contribution of Germline Predisposition Gene Mutations to Breast Cancer Risk in African American Women
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 10, October 2020, Page 1071, https://doi.org/10.1093/jnci/djaa086
Corrigendum
Corrigendum: Breast cancer mortality after implementation of organized population-based breast cancer screening in Norway
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 10, October 2020, Pages 1072–1074, https://doi.org/10.1093/jnci/djaa045
Corrigendum: Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 10, October 2020, Page 1075, https://doi.org/10.1093/jnci/djaa065
Corrigendum: Genetic Factors, Adherence to Healthy Lifestyle Behavior, and Risk of Invasive Breast Cancer Among Women in the UK Biobank
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 10, October 2020, Page 1076, https://doi.org/10.1093/jnci/djaa085
Corrigendum: Prediagnostic Plasma Bile Acid Levels and Colon Cancer Risk: A Prospective Study
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 10, October 2020, Page 1077, https://doi.org/10.1093/jnci/djaa094
